Eli Lilly and Company (LLY) 74.33 $LLY
Incyte Gains on Jakafi's Breakthrough Status for Acute GVHD
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 5:07PM CDT
Incyte (INCY) announced that the FDA has granted Breakthrough Therapy status to Jakafi for the treatment of patients with acute graft-versus-host disease.
INCY: 76.98 (-4.68), LLY: 74.33 (+0.39), BMY: 70.61 (-2.03), NVS: 77.10 (-3.57)
Diabetes Scholars Foundation Announces 2016 Scholarship Recipients
PR Newswire - Thu Jun 23, 9:00AM CDT
If the caliber of students receiving a Lilly Diabetes Tomorrow's Leaders Scholarship is any indication, the future is in good hands. The 2016 scholarship winners, announced today online at www.diabetesscholars.org by the Diabetes Scholars Foundation (Foundation), refused to let type 1 diabetes stand in the way of academic and community service excellence.
LLY: 74.33 (+0.39)
MacroStat Receives 2016 Lilly Global Supplier Award
BusinessWire - Wed Jun 22, 10:51AM CDT
MacroStat, a leading biometrics CRO fully owned by Tigermed (ChiNext SZ: 300347), has received the 2016 Lilly Global Supplier Award that recognizes MacroStat's outstanding performance in the area of biometrics services for Eli Lilly and Company (NYSE: LLY).
LLY: 74.33 (+0.39)
Cancer Drug News Issue - Global Expansion of Portrazza will Aid in Supporting Eli Lilly's Lung Cancer Franchise - Research and Markets
BusinessWire - Tue Jun 21, 12:32PM CDT
Research and Markets has announced the addition of the "Cancer Drug News Issue 670" report to their offering.
LLY: 74.33 (+0.39)
Lilly Declares Third-Quarter 2016 Dividend
PR Newswire - Mon Jun 20, 12:00PM CDT
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2016 of $0.51 per share on outstanding common stock.
LLY: 74.33 (+0.39)
Elanco, EnBiotix Establish Collaboration Exploring Engineered Phage Technology
BusinessWire - Thu Jun 16, 7:00AM CDT
Today Elanco Animal Health, a division of Eli Lilly and Company, (NYSE: LLY) and EnBiotix, Inc., announced a collaboration to explore the application of EnBiotix's engineered phage technology in specific animal health targets. If successful, this endeavor could result in potential alternatives for traditional antibiotics in animals.
LLY: 74.33 (+0.39)
German Supreme Court Grants Lilly Appeal in Alimta® Vitamin Regimen Patent Lawsuit
PR Newswire - Tue Jun 14, 5:15PM CDT
The German Federal Supreme Court has granted the appeal by Eli Lilly and Company (NYSE: LLY) in the case of Eli Lilly and Company v. Actavis, vacating the prior decision denying infringement. The German Supreme Court returned the case to the Court of Appeal (Dusseldorf) for further proceedings. The case concerns whether Lilly's vitamin regimen patent for Alimta® (pemetrexed disodium) would be infringed by a generic competitor that had stated an intention to market a dipotassium salt form of pemetrexed in Germany.
LLY: 74.33 (+0.39)
Merck's Biosimilar Version of Lantus Tops Phase III Studies
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 5:14PM CDT
Merck (MRK) announced encouraging data from two phase III studies on MK-1293 for the treatment of type I and type II diabetes.
MRK: 55.88 (-1.80), LLY: 74.33 (+0.39), BMY: 70.61 (-2.03), SNY: 38.45 (-2.74)
Aarti Shah named chief information officer
PR Newswire - Mon Jun 13, 12:00PM CDT
Eli Lilly and Company (NYSE: LLY) today announced the promotion of Aarti Shah, Ph.D., to senior vice president and chief information officer effective July 1. She has been the global brand development leader for immunology since 2013.
LLY: 74.33 (+0.39)
Incyte's Jakafi Positive in Phase III for Polycythemia Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 8:15AM CDT
Incyte (INCY) announced new 28-week data from the phase III RESPONSE-2 study on Jakafi for the treatment of polycythemia vera.
INCY: 76.98 (-4.68), ABBV: 59.86 (-1.45), LLY: 74.33 (+0.39), BMY: 70.61 (-2.03)
Global Migraine Market Report: 2016 Edition Featuring Amgen, Teva Pharmaceuticals, Eli Lilly and Company & AstraZeneca - Research and Markets
BusinessWire - Fri Jun 10, 4:14AM CDT
Research and Markets has announced the addition of the "Global Migraine Market Report: 2016 Edition" report to their offering.
AMGN: 146.45 (-5.82), LLY: 74.33 (+0.39)
Data in The Lancet Show Olaratumab Plus Doxorubicin Offered 11.8-Month Increase in Overall Survival in Patients with Advanced Soft Tissue Sarcoma, as Reported by Lilly and Memorial Sloan Kettering Researchers
PR Newswire - Thu Jun 09, 5:30PM CDT
Eli Lilly and Company (NYSE: LLY) announced that The Lancet published detailed results from a Phase 2 study evaluating the efficacy and safety of olaratumab, an investigational compound, in combination with doxorubicin chemotherapy in patients with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery. STS is a rare cancer for which patients have limited treatment options. The study met its primary endpoint of progression-free survival (PFS) and showed a statistically significant improvement in overall survival (OS), a key secondary endpoint.
LLY: 74.33 (+0.39)
Lilly and American Migraine Foundation Announce $1 Million Grant for Launch of First Patient Registry to Advance Research and Development in Migraine
PR Newswire - Thu Jun 09, 11:00AM CDT
Eli Lilly and Company (NYSE: LLY) and the American Migraine Foundation announced today that Lilly will provide a $1 million grant to the American Migraine Foundation to sponsor the development of the American Registry for Migraine Research (ARMR), a large-scale, publicly-accessible headache registry and biological repository that will contain clinical, biologic and neuroimaging data to further advance the research and discovery of new treatments for migraine.
LLY: 74.33 (+0.39)
Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs
CNW Group - Thu Jun 09, 5:45AM CDT
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that data from a pivotal long-term extension study, RA-BEYOND, was presented at the Annual European Congress of Rheumatology (EULAR 2016) in London. The findings demonstrate that baricitinib was superior to placebo at inhibiting progressive radiographic joint damage in patients with rheumatoid arthritis (RA).
INCY: 76.98 (-4.68), LLY: 74.33 (+0.39)
Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA)
CNW Group - Thu Jun 09, 5:45AM CDT
Pivotal trials show treatment with baricitinib resulted in significant improvements in pain, fatigue and ability to perform daily activities compared to methotrexate - the current standard of care - and adalimumab (Humira(®))*
INCY: 76.98 (-4.68), LLY: 74.33 (+0.39)
Studies Demonstrate Lilly's Taltz® (ixekizumab) Maintained or Achieved High Levels of Skin Clearance for Patients with Moderate-to-Severe Plaque Psoriasis through 60 Weeks: Results Published in the New England Journal of Medicine
CNW Group - Wed Jun 08, 4:00PM CDT
Eli Lilly and Company (NYSE: LLY) announced today that the New England Journal of Medicine has published detailed results from three pivotal Phase 3 studies--UNCOVER-1, UNCOVER-2 and UNCOVER-3--that demonstrated the efficacy and safety of Taltz(®) (ixekizumab) through 60 weeks in patients with moderate-to-severe plaque psoriasis. This publication also detailed 12-week efficacy data for patients treated with Taltz in UNCOVER-1.
LLY: 74.33 (+0.39)
Fujitsu and Box Sign MoU for Strategic Content Management Partnership
JCN Newswire - Wed Jun 08, 4:48AM CDT
BOX: 11.11 (-0.34), LLY: 74.33 (+0.39)
Incyte Gains on Jakafi's Breakthrough Status for Acute GVHD
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 5:07PM CDT
Incyte (INCY) announced that the FDA has granted Breakthrough Therapy status to Jakafi for the treatment of patients with acute graft-versus-host disease.
INCY: 76.98 (-4.68), LLY: 74.33 (+0.39), BMY: 70.61 (-2.03), NVS: 77.10 (-3.57)
Diabetes Scholars Foundation Announces 2016 Scholarship Recipients
PR Newswire - Thu Jun 23, 9:00AM CDT
If the caliber of students receiving a Lilly Diabetes Tomorrow's Leaders Scholarship is any indication, the future is in good hands. The 2016 scholarship winners, announced today online at www.diabetesscholars.org by the Diabetes Scholars Foundation (Foundation), refused to let type 1 diabetes stand in the way of academic and community service excellence.
LLY: 74.33 (+0.39)
MacroStat Receives 2016 Lilly Global Supplier Award
BusinessWire - Wed Jun 22, 10:51AM CDT
MacroStat, a leading biometrics CRO fully owned by Tigermed (ChiNext SZ: 300347), has received the 2016 Lilly Global Supplier Award that recognizes MacroStat's outstanding performance in the area of biometrics services for Eli Lilly and Company (NYSE: LLY).
LLY: 74.33 (+0.39)
Cancer Drug News Issue - Global Expansion of Portrazza will Aid in Supporting Eli Lilly's Lung Cancer Franchise - Research and Markets
BusinessWire - Tue Jun 21, 12:32PM CDT
Research and Markets has announced the addition of the "Cancer Drug News Issue 670" report to their offering.
LLY: 74.33 (+0.39)
Lilly Declares Third-Quarter 2016 Dividend
PR Newswire - Mon Jun 20, 12:00PM CDT
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2016 of $0.51 per share on outstanding common stock.
LLY: 74.33 (+0.39)
Elanco, EnBiotix Establish Collaboration Exploring Engineered Phage Technology
BusinessWire - Thu Jun 16, 7:00AM CDT
Today Elanco Animal Health, a division of Eli Lilly and Company, (NYSE: LLY) and EnBiotix, Inc., announced a collaboration to explore the application of EnBiotix's engineered phage technology in specific animal health targets. If successful, this endeavor could result in potential alternatives for traditional antibiotics in animals.
LLY: 74.33 (+0.39)
German Supreme Court Grants Lilly Appeal in Alimta® Vitamin Regimen Patent Lawsuit
PR Newswire - Tue Jun 14, 5:15PM CDT
The German Federal Supreme Court has granted the appeal by Eli Lilly and Company (NYSE: LLY) in the case of Eli Lilly and Company v. Actavis, vacating the prior decision denying infringement. The German Supreme Court returned the case to the Court of Appeal (Dusseldorf) for further proceedings. The case concerns whether Lilly's vitamin regimen patent for Alimta® (pemetrexed disodium) would be infringed by a generic competitor that had stated an intention to market a dipotassium salt form of pemetrexed in Germany.
LLY: 74.33 (+0.39)
Merck's Biosimilar Version of Lantus Tops Phase III Studies
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 5:14PM CDT
Merck (MRK) announced encouraging data from two phase III studies on MK-1293 for the treatment of type I and type II diabetes.
MRK: 55.88 (-1.80), LLY: 74.33 (+0.39), BMY: 70.61 (-2.03), SNY: 38.45 (-2.74)
Aarti Shah named chief information officer
PR Newswire - Mon Jun 13, 12:00PM CDT
Eli Lilly and Company (NYSE: LLY) today announced the promotion of Aarti Shah, Ph.D., to senior vice president and chief information officer effective July 1. She has been the global brand development leader for immunology since 2013.
LLY: 74.33 (+0.39)
Incyte's Jakafi Positive in Phase III for Polycythemia Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 8:15AM CDT
Incyte (INCY) announced new 28-week data from the phase III RESPONSE-2 study on Jakafi for the treatment of polycythemia vera.
INCY: 76.98 (-4.68), ABBV: 59.86 (-1.45), LLY: 74.33 (+0.39), BMY: 70.61 (-2.03)
Global Migraine Market Report: 2016 Edition Featuring Amgen, Teva Pharmaceuticals, Eli Lilly and Company & AstraZeneca - Research and Markets
BusinessWire - Fri Jun 10, 4:14AM CDT
Research and Markets has announced the addition of the "Global Migraine Market Report: 2016 Edition" report to their offering.
AMGN: 146.45 (-5.82), LLY: 74.33 (+0.39)
Data in The Lancet Show Olaratumab Plus Doxorubicin Offered 11.8-Month Increase in Overall Survival in Patients with Advanced Soft Tissue Sarcoma, as Reported by Lilly and Memorial Sloan Kettering Researchers
PR Newswire - Thu Jun 09, 5:30PM CDT
Eli Lilly and Company (NYSE: LLY) announced that The Lancet published detailed results from a Phase 2 study evaluating the efficacy and safety of olaratumab, an investigational compound, in combination with doxorubicin chemotherapy in patients with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery. STS is a rare cancer for which patients have limited treatment options. The study met its primary endpoint of progression-free survival (PFS) and showed a statistically significant improvement in overall survival (OS), a key secondary endpoint.
LLY: 74.33 (+0.39)
Lilly and American Migraine Foundation Announce $1 Million Grant for Launch of First Patient Registry to Advance Research and Development in Migraine
PR Newswire - Thu Jun 09, 11:00AM CDT
Eli Lilly and Company (NYSE: LLY) and the American Migraine Foundation announced today that Lilly will provide a $1 million grant to the American Migraine Foundation to sponsor the development of the American Registry for Migraine Research (ARMR), a large-scale, publicly-accessible headache registry and biological repository that will contain clinical, biologic and neuroimaging data to further advance the research and discovery of new treatments for migraine.
LLY: 74.33 (+0.39)
Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs
CNW Group - Thu Jun 09, 5:45AM CDT
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that data from a pivotal long-term extension study, RA-BEYOND, was presented at the Annual European Congress of Rheumatology (EULAR 2016) in London. The findings demonstrate that baricitinib was superior to placebo at inhibiting progressive radiographic joint damage in patients with rheumatoid arthritis (RA).
INCY: 76.98 (-4.68), LLY: 74.33 (+0.39)
Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA)
CNW Group - Thu Jun 09, 5:45AM CDT
Pivotal trials show treatment with baricitinib resulted in significant improvements in pain, fatigue and ability to perform daily activities compared to methotrexate - the current standard of care - and adalimumab (Humira(®))*
INCY: 76.98 (-4.68), LLY: 74.33 (+0.39)
Studies Demonstrate Lilly's Taltz® (ixekizumab) Maintained or Achieved High Levels of Skin Clearance for Patients with Moderate-to-Severe Plaque Psoriasis through 60 Weeks: Results Published in the New England Journal of Medicine
CNW Group - Wed Jun 08, 4:00PM CDT
Eli Lilly and Company (NYSE: LLY) announced today that the New England Journal of Medicine has published detailed results from three pivotal Phase 3 studies--UNCOVER-1, UNCOVER-2 and UNCOVER-3--that demonstrated the efficacy and safety of Taltz(®) (ixekizumab) through 60 weeks in patients with moderate-to-severe plaque psoriasis. This publication also detailed 12-week efficacy data for patients treated with Taltz in UNCOVER-1.
LLY: 74.33 (+0.39)
Fujitsu and Box Sign MoU for Strategic Content Management Partnership
JCN Newswire - Wed Jun 08, 4:48AM CDT
BOX: 11.11 (-0.34), LLY: 74.33 (+0.39)
